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Abstract
Objectives: Hypoglycemia induced by electroacupuncture (EA) is due to an increase 
of insulin secretion and/or mediation of β-endorphin. We applied EA at the Zusanli 
(ST.36) acupuncture point (acupoint) in combination with rosiglitazone (TZD) admin-
istration to evaluate their effect on plasma glucose and to explore possible mecha-
nisms of action. 
Methods: Thirty six normal adult Wistar rats were randomly divided into four groups: 
the 0.1 mg/kg TZD group (0.1TZD), 0.1 mg/kg TZD and EA group (0.1TZD + EA), EA 
group, and control group. In other experiments, streptozotocin was used to induce 
type 2 diabetes mellitus in neonatal rats; these were then randomly divided into a 
0.1TZD group, 0.1TZD + EA group, and EA group and changes in plasma glucose and 
insulin concentrations evaluated. 
Results: A marked hypoglycemic response was observed in the normal rat 0.1TZD, 
0.1TZD + EA and EA groups, with the response more significant in the 0.1TZD + EA group 
than in the 0.1TZD group. Among the diabetic animals, the hypoglycemic responses 
in the 0.1TZD + EA and EA groups were greater than in the 0.1TZD group. In both the 
normal and diabetic rats, insulin secretion was increased by EA or 0.1TZD + EA treat-
ment, but not by 0.1TZD. 
Conclusions: The plasma glucose lowering action of rosiglitazone was increased 
by EA in both normal and diabetic rats, indicating that the application of EA may 
enhance the hypoglycemic action of this insulin sensitizer.
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1. Introduction
The natural history of type 2 diabetes mellitus 
(T2DM) in the prediabetic state is characterized by 
insulin resistance and compensatory hyperinsuline-
mia and/or partially impaired secretion of insulin. 
Resistance to insulin is the reduction of the biologi-
cal response to insulin and can occur 5 to 10 years 
before diabetes is diagnosed. There are many meth-
ods to reduce insulin resistance, including changing 
diet, exercise, medicine, and Chinese medicine, in 
addition to acupuncture, moxibustion, and massage 
[1−3]. But there are limitations to any single ther-
apy, especially for insulin sensitizers. In our experi-
ence, insulin sensitizers do not have efficacious 
hypoglycemic effects in the short term; they must 
be taken over a period of time to improve insulin 
resistance. According to traditional Chinese medi-
cine theory, acupuncture regulates ‘Qi and Blood’ 
and likely adjusts the bioavailability of substances 
taken internally, influencing, for example, absorp-
tion, distribution, metabolism, or excretion of sub-
stances [4]. This characteristic could help improve 
insulin resistance or the utility of insulin. Thus it 
was hypothesized in the present study that electro-
acupuncture (EA) could increase the hypoglycemic 
action of the insulin sensitizer rosiglitazone (TZD). 
Previously, opioid receptors in the pancreas were 
investigated for their roles in the regulation of 
plasma glucose [5,6]. In addition, β-endorphin en-
hances insulin secretion [7] and endogenous opioid 
peptides are increased by EA to promote insulin 
secretion, inducing a hypoglycemic response in ani-
mals [8,9]. This improvement of insulin sensitivity 
was related to the downregulation of the plasma 
free fatty acid (FFA) concentrations and by EA [10]. 
Further more, EA has been reported to effectively 
improve abnormal lipid metabolism and reduced 
fat accumulation in obese rats, the latter effect 
possibly closely associated with its effect in regu-
lating the balance between leptin and insulin 
concentrations [11].
Wistar rats have been widely used in research 
since the 1920s [12] and alloxan or streptozotocin, 
which cause damage to pancreatic cells via free-
radical cytotoxicity, are used to induce T2DM in lab-
oratory animals [13]. Streptozotocin is commonly 
administered to neonatal rats to create a T2DM-like 
animal model [14,15] that has been useful in under-
standing the complex pathogenesis of T2DM. Injec-
tion of this anticancer drug into rats during the 
neonatal period leads to the major features typically 
experienced by diabetic patients, including hyper-
glycemia, polyphagia, polydipsia, polyuria, and ab-
normal glucose tolerance [16]. This T2DM-like model 
has shown an insulin resistance state concurrent 
with damage to pancreatic islet cells [17].
During intravenous glucose tolerance tests 
(IVGTT), plasma glucose concentrations returned to 
normal values early in normal rats, while EA en-
hanced the hypoglycemic effect of the insulin chal-
lenge test (ICT) in streptozotocin-induced diabetic 
rats [2]. The insulin sensitizer, rosiglitazone, improves 
insulin sensitivity via activation of PPAR-γ receptors, 
but does not enhance the secretion of insulin [18]. 
Nonetheless, recent reports have shown adverse ef-
fects on the liver, fluid retention, and congestive 
heart failure [19]. The combination of the advantages 
of EA’s effects on the regulation of plas ma glucose 
and insulin with those of an insulin sensitizer com-
prises a new therapy for improved handling of dia-
betic disorders. Thus the main purpose of this study 
was to evaluate the combination of EA and drug 
therapy involving an insulin sensitizer, rosiglitazone, 
for enhancing hypoglycemic effects. In addition, we 
studied the relative mechanisms of EA’s synergism 
with rosiglitazone by assaying plasma insulin concen-
trations in normal and T2DM-like animal models.
2. Methods
2.1. Animal model
Male Wistar rats, aged 8−10 weeks, were obtained 
from the National Laboratory Animal Center in 
Taiwan. T2DM was induced in 2-day-old neonatal rats 
by intraperitoneal (i.p.) injection of 60 mg/kg of 
streptozotocin (Sigma Company, St. Louis, MO, USA), 
as described previously [8,16]. All animals were main-
tained under a 12:12 hour light-dark cycle (starting 
at 6:00 a.m.) in a temperature controlled room 
(25 ± 1°C) at the Animal Center of China Medical 
University with food (Purina Rat Chow) and water ad 
libitum. Animals were treated in accordance with 
the National Institute of Health (NIH) Guide for the 
Care and Use of Laboratory Animals.
2.2. Laboratory determinations
Plasma glucose (mmol/L) concentrations were 
determined using a spectrophotometric system 
(COBAS System, Roche Diagnostics Ltd., Rotkreuz, 
Switzerland) and commercially available enzymatic 
kits run in duplicate. The plasma insulin concen-
trations were measured using an ELISA kit (Linco 
Res earch, St. Charles, Missouri, USA) [20]. In brief, 
sam ples were incubated for 2 hours at room tem-
perature in a shaker and exposed to peroxidase-
conjugate and antibodies bound to a microtitration 
well, a conjugate produced by reaction with 3,3,5,5-
tetramethylbenzidine, the reaction stopped by add-
ing 1 M sulfuric acid 50 μl, the mixture shaken to 
produce a colorimetric endpoint, and measured 
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spectrophotometrically. The values obtained were 
in pmol of peptide per liter of plasma. 
2.3. Experimental protocol
Thirty-six normal rats were randomly divided into 
four groups: 0.1 mg/kg TZD group (0.1TZD), 0.1 mg/
kg TZD + EA group (0.1TZD + EA), EA group, and a con-
trol group (saline). Twenty-four T2DM-like rats were 
also randomly divided into three groups: 0.1TZD, 
0.1TZD + EA, and EA group. All animals were fasted 
for 12 hours and 0.1 mg/kg TZD given by oral admin-
istration to the 0.1TZD and 0.1TZD + EA groups, with 
the control group was treated with a similar volume 
of normal saline. All experiments were performed 
under anesthesia using pentobarbital (40 mg/kg, i.p.).
2.4. Electroacupuncture
In the EA group, the Zusanli acupoints were located 
bilaterally at the anterior tibia muscles near the 
knees, according to a previous study. Two acupunc-
ture needles (0.5 inch in length and 32-gauge) were 
inserted 2−5 mm into the muscle layer at both Zusanli 
acupoints, with the positive lead on the right leg and 
the negative lead on the left, and the EA apparatus 
adjusted to 15 Hz/10 mA (Han’s Healthronics Likon, 
Taipei, Taiwan). Blood samples were taken from the 
femoral vein 30 minutes after TZD or saline treat-
ment and after following 30 minutes EA. 
2.5. Statistical analysis
The hypoglycemic activity (%) was calculated as 
follows: (Gi−Gt) × 100/Gi; Gi was the initial glucose 
concentration and Gt the concentration after treat-
ment. All values were expressed as means ± SEM in 
the figures and tables. The Wilcoxon signed-rank test 
was applied to assess differences by treatment in 
each group. The Kruskal-Wallis test was applied to 
compare the hypoglycemic effect in two or more 
different treatment groups, and the Mann-Whitney 
test was applied to compare the differences be-
tween two independent groups. For all comparisons, 
a p-value less than 0.05 (two-sided) was considered 
statistically significant. 
3. Results
3.1. Baseline data
Normal, neonatal Wistar rats were successfully in-
duced to develop T2DM using streptozotocin. The 
resulting T2DM-like rats had mean plasma glucose 
concentrations of 141.7 ± 5.0 mg/dL, higher than the 
concentration in normal rats (122.6 ± 2.5 mg/dL, 
p < 0.05), and lower plasma insulin concentrations 
(p < 0.05) than normal rats (Table 1). Additionally, 
the diabetic symptoms of polyphagia, polydipsia, 
and polyuria in these T2DM-like rats were signifi-
cantly greater than among normal Wistar rats 
during the experimental period.
3.2.  Effect of combined therapy in 
normal rats
The fasting plasma glucose and insulin concentra-
tions in the four groups (n = 9) of normal rats did 
not differ significantly. A significant hypoglycemic 
response was produced by the treatments in the 
0.1TZD, 0.1TZD + EA, and EA groups. Additionally, 
greater hypoglycemic activity (%) was observed in 
the 0.1TZD + EA and EA groups than in the 0.1TZD 
group (Table 2). 
Table 1  The baseline data between normal Wistar 
and T2DM rats
 Wistar (n = 19) T2DM (n = 19) p value
Glucose 122.6 ± 2.5 141.7 ± 5.0** 0.0021
 (mg/dL)
Insulin (IU/L) 0.069 ± 0.008 0.039 ± 0.004** 0.0017 
Values as mean ± SEM; n = number of animals; T2DM rats = 
type 2 diabetic mellitus rats; independent groups compared 
using non-parametric Mann-Whitney test, **p < 0.01.
Table 2 Plasma glucose concentrations effects from EA and drug combined therapy in normal Wistar rats
Group (n = 9) Before treatment After treatment Hypoglycemic activity (%)
0.1TZD  125 ± 2 104 ± 2* −17 ± 2,B
0.1TZD + EA  124 ± 2 86 ± 2* −31 ± 2,A
EA  121 ± 3 85 ± 3* −29 ± 2,A
Saline (control)  117 ± 7 109 ± 3 −7 ± 6,C
Plasma glucose concentrations as mean ± SEM (mg/dL) after 12 hours fasting; n = 9; EA = electroacupuncture; 0.1TZD = rosiglita-
zone 0.1 mg/kg; non-parametric Wilcoxon signed-rank test to assess differences in the means of each group; *p < 0.01; Kruskal-
Wallis test to compare hypoglycemic effect of different treatment groups, followed by non-parametric Mann-Whitney test to 
compare difference between two independent groups, A > B > C, p < 0.05.
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There was no significant change observed in the 
control group, while the plasma insulin concentra-
tions were elevated significantly in the 0.1TZD + EA 
and EA groups (p < 0.05), but remained unchanged 
in the 0.1TZD (p = 0.73) and saline (p = 0.46) groups 
(Figure 1).
3.3.  The effect of combined therapy in 
T2DM-like rats
The fasting plasma glucose and insulin concentra-
tions in the three groups of T2DM-like rats did not 
differ. A marked hypoglycemic response (p < 0.05) 
was obtained in the 0.1TZD + EA and EA groups and 
the hypoglycemic activity (%) was stronger in the 
0.1TZD + EA and EA groups compared with the 
0.1TZD group (Table 3). Insulin secretion was also 
enhanced in the 0.1TZD + EA and EA groups, but not 
in 0.1TZD group (p < 0.05) (Figure 2).
4. Discussion
EA treatment was combined with an insulin sensitizer 
(rosiglitazone) to examine the hypoglycemic effects 
in normal rats and rats with streptozotocin-induced 
T2DM. Insulin and glucose concentrations were 
assayed to explore the plasma glucose lowering ef-
fects of the different treatments. Among the T2DM-
like rats, higher plasma glucose and lower insulin 
concentrations were found at baseline than for nor-
mal Wistar rats. We considered that this early stage 
of streptozotocin-induced T2DM in rats indicated a 
major partial dysfunction of insulin secretion rather 
than insulin resistance. The mixed types of patho-
genesis observed here in the T2DM-like models cor-
related closely with the early stage of disease after 
induction [17]. 
Similar to previous results, EA appeared to im-
prove glucose regulation by stimulating insulin se-
cretion and/or improving insulin sensitivity [2,3,8]. 
The 0.1 mg/kg of TZD used here was near the recom-
mended maximal dose (8 mg) for clinical applications 
to a 60-kg human adult. In normal Wistar rats, 17% 
hypoglycemic activity was obtained 1 hour after 
feeding 0.1 mg/kg TZD (Table 2). In T2DM-like rats, no 
obvious hypoglycemic response was observed in the 
0.1TZD group (Table 3), a result possibly due to the 
insufficiency of insulin action in these T2DM-like rats. 
Because no significant change in plasma glucose was 
obtained in the saline group of normal rats, saline 
treatments in the T2DM-like rats were not performed.
Usually, insulin resistance is the main mecha-
nism of T2DM observed in the clinic, unless the 
Wistar insulin secretion
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Figure 1 Effects of EA and TZD therapy on plasma insu-
lin concentration in normal Wistar rats. EA = electroacu-
puncture; 0.1TZD = rosiglitazone; non-parametric Wilcoxon 
signed-rank test to assess differences in means within 
each group, *p < 0.05.
Table 3 Plasma glucose concentrations effected by EA and drug combined therapy in T2DM rats
Group (n = 8) Before treatment After treatment Hypoglycemic activity (%)
0.1TZD  143 ± 5 142 ± 6  −1 ± 2,B
0.1TZD + EA  138 ± 13 93 ± 10* −33 ± 3,A
EA 137 ± 9 89 ± 7* −35 ± 5,A
Plasma glucose concentrations as mean ± SEM (mg/dL) after 12 hours of fasting, n = number of animals; EA = received electroacu-
puncture; 0.1TZD = received rosiglitazone; non-parametric Wilcoxon signed-Rank test to assess differences in the means of each 
group, *p < 0.05; Kruskal Wallis test to compare hypoglycemic effect of different treatment groups, followed by non-parametric 
Mann-Whitney test to compare differences by treatment within each independent group, A > B, p < 0.05.
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Figure 2 Effects of EA and TZD therapy on plasma insulin 
concentration in T2DM rats. EA = electroacupuncture; 
0.1TZD = rosiglitazone; non-parametric Wilcoxon signed-
rank test to assess differences in the means of each 
group, *p < 0.05.
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patient has β-cell function failure in the pancreas; 
T2DM patients are always hyperinsulinemic. In this 
study, the growth of T2DM-like rats showed damaged 
pancreatic function combined with partial insulin 
resistance, leading to higher plasma glucose. We 
considered that the pancreatic islets responded to 
EA for lowering the plasma glucose [8]. This sup-
ports the results obtained here; secretion of insu-
lin was promoted by the combined treatment of EA 
and TZD (Figure 1). In another animal model stud-
ied in 2000, in which high fat diets administered to 
create insulin resistance were followed by strepto-
zotocin administration to induce T2DM, the pathol-
ogy of animals appeared more similar to clinical 
T2DM [21]. This model merits further testing of the 
study’s hypothesis that combined treatment with EA 
and TZD may increase the plasma glucose lowering 
action more than treatment with EA or TZD alone.
A significant hypoglycemic response was observed 
in the 0.1TZD + EA and EA groups, both in normal and 
T2DM-like rats (Tables 2 and 3), and insulin secretion 
increased in both groups (Figures 1 and 2). Accord-
ing to previous a report [8], the hypoglycemic 
action of EA was related to endogenous β-endorphin 
concentrations, which enhances insulin secretion. 
Thus a more significant hypoglycemic response in 
the combined EA and TZD group was observed here 
compared with the TZD-only group (Tables 2 and 3). 
While Lin et al documented the increase in plasma 
opioids due to EA, the effect of opioids on insulin 
sensitivity in addition to TZD is still unclear; fur-
ther elucidating studies are needed. 
In conclusion, this study demonstrated that EA 
treatment increased the plasma glucose lowering 
action of rosiglitazone in both normal and T2DM-
like rats. Thus the application of EA may enhance the 
hypoglycemic action of this insulin sensitizer via en-
hanced insulin secretion in neonatal streptozotocin-
induced diabetic rats.
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